Novo Nordisk’s Oral Wegovy Surges to 18,410 U.S. Prescriptions in Debut Week, Signaling Pill Preference in Weight-Loss Boom

Novo Nordisk’s groundbreaking oral version of its blockbuster weight-loss drug Wegovy racked up 18,410 prescriptions across the United States in its first full week of availability ending January 16, 2026, outpacing early launches of rival GLP-1 therapies. The pill, which hit pharmacies on January 5 following FDA approval in late December 2025, notched 3,071 scripts in its initial four days alone, according to IQVIA data cited by analysts. This rapid uptake underscores growing patient demand for needle-free options amid soaring obesity rates affecting over 100 million Americans.

Launch Details and Market Momentum

Novo Nordisk launched the Wegovy pill as the first oral GLP-1 receptor agonist approved for chronic weight management in adults with obesity or overweight plus weight-related conditions like hypertension. Available in doses of 1.5 mg (starter), 4 mg, 9 mg, and 25 mg, the once-daily tablet mimics the gut hormone GLP-1 to curb appetite, slow gastric emptying, and regulate blood sugar—mechanisms identical to its weekly injectable counterpart. Priced accessibly at $149 per month for starter and 4 mg doses initially (rising to $199 for 4 mg after April), and $299 for higher strengths, it’s offered via 70,000+ pharmacies like CVS and Costco, plus telehealth platforms such as Ro and LifeMD.

Analysts hailed the start as “surpassing the launch metrics of other GLP-1 products,” with Guggenheim noting its edge over Eli Lilly’s Zepbound autoinjector, which hit about 1,300 new patients in its 2023 debut week. Early data shows the pill reaching nearly 3,100 patients by January 9, boosting Novo shares despite a dip in overall Wegovy franchise scripts. Investors eye whether this first-mover pill advantage will help Novo reclaim ground from Lilly in the $100 billion-plus obesity market.

Clinical Evidence Backing the Pill

The Wegovy pill’s efficacy stems from the phase III OASIS 4 trial, where 25 mg oral semaglutide yielded 16.6% mean weight loss at 64 weeks among adherent adults with obesity (versus 2.7% for placebo), with one-third hitting 20%+ loss. Treatment-policy estimates (factoring real-world adherence) showed 13.6% loss, alongside cardiometabolic gains like normalized blood glucose in 70%+ of prediabetics and reduced blood pressure.

These results mirror injectable Wegovy’s STEP trials (15-17% loss) but offer convenience, as the pill’s formulation protects semaglutide from stomach acid degradation. About 76% of trial participants lost 5%+ body weight (versus 31% on placebo), with average losses of 33 pounds from a 235-pound baseline. Novo positions it for those with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities, always paired with diet and exercise.

Expert Insights on Adoption Drivers

“We observe that this is outperforming other GLP-1 introductions,” Guggenheim analysts wrote, attributing success to patient aversion to needles. Obesity specialist Dr. Jorge Moreno of Yale Medicine told media that pill-tolerant patients struggling with injections could switch seamlessly, as both forms share similar effects.

Endocrinologist Dr. Judith Korner, head of Columbia’s Metabolism and Weight Center, noted weekly shots might sustain effects longer, but daily pills allow quicker side-effect resolution: “If patients feel unwell, they can simply stop for a day.” Neither expert was involved in Novo’s trials, providing independent validation. Demand reflects broader trends: GLP-1s like Wegovy have transformed obesity care, with U.S. prescriptions topping 15 million monthly.

Public Health Ripple Effects

This launch could democratize access to proven therapies, as pills sidestep injection barriers like needle phobia, which deter 10-20% of eligible patients. With U.S. obesity at 42% and linked to heart disease, diabetes, and 300,000+ annual deaths, scaling GLP-1s might avert billions in healthcare costs—Wegovy alone cut cardiovascular risks in trials. Practical takeaways: Eligible adults should discuss with providers; self-pay starts low, and insured pay as little as $25/month via savings cards.

For India’s context, where obesity tripled to 5.4% since 1990 per WHO, similar oral GLP-1s could inspire local strategies, though affordability remains key in diverse markets like Himachal Pradesh.

Challenges and Balanced Perspectives

Side effects mirror injectables: 75% report mild-moderate GI issues like nausea, diarrhea, vomiting, and constipation, with 7-10% discontinuing; serious events were rarer (3.9% vs. 8.8% placebo). Boxed warnings flag thyroid cancer risk (from rodent data) and pancreatitis/gallbladder issues. Adherence challenges persist—18% quit in trials—due to daily dosing versus weekly shots.

Critics note costs ($3,000+ yearly list price) limit equity, and long-term data lags; weight regain occurs post-stopping without lifestyle changes. Eli Lilly’s upcoming orforglipron pill looms as competition. Not for kids yet (injections approved 12+). “Pills expand options but aren’t magic—sustainable habits matter,” per experts.

Competitive Landscape

This table highlights the pill’s convenience amid fierce rivalry.

Novo’s strong start positions oral Wegovy as a pivotal evolution in obesity care, blending efficacy with accessibility. Yet, its success hinges on sustained uptake, supply, and integration with holistic health efforts.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• Reuters. “Novo’s Wegovy pill tracks 18,410 prescriptions in first full week since launch.” Jan 23, 2026. https://www.reuters.com/business/healthcare-pharmaceuticals/novos-wegovy-pill-tracks-18410-prescriptions-first-full-week-since-launch-2026-01-23/[reuters]​